AbbVie’s IL-23 blocker shows efficacy in psoriasis trial
An experimental therapy being developed by AbbVie for the treatment of patients with moderate to severe plaque psoriasis has hit key targets in a pivotal late-stage trial.
Read More
Tag: PASI90
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
